Clinical trial
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
NCT00014287 · University of Pittsburgh, Other · Withdrawn
Key facts
| NCT number | NCT00014287 |
|---|---|
| Title | Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer |
| Official title | Intravesical Gemcitabine Therapy for BCG-Refractory Superficial Bladder Cancer: A Phase I and Pharmacokinetic Study |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride |
| Enrollment | 0 |
| Start date | Sep 1, 2000 |
| First posted | Jan 7, 2004 |
| Last update posted | Dec 19, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: